A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors. (NCT03918278)
MK-0482-001
This trial is No longer recruiting
Registration number NCT03918278
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Mark Voskoboynik
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR